dc.contributor.author | Kusuma, Bhaskar Reddy | |
dc.contributor.author | Duerfeldt, Adam S. | |
dc.contributor.author | Blagg, Brian S. J. | |
dc.date.accessioned | 2017-05-04T18:39:43Z | |
dc.date.available | 2017-05-04T18:39:43Z | |
dc.date.issued | 2011-12-01 | |
dc.identifier.citation | Kusuma, B. R., Duerfeldt, A. S., & Blagg, B. S. J. (2011). Synthesis and biological evaluation of arylated novobiocin analogs as Hsp90 inhibitors. Bioorganic & Medicinal Chemistry Letters, 21(23), 7170–7174. http://doi.org/10.1016/j.bmcl.2011.09.073 | en_US |
dc.identifier.uri | http://hdl.handle.net/1808/23893 | |
dc.description.abstract | Novobiocin analogs lacking labile glycosidic ether have been designed, synthesized and evaluated for Hsp90 inhibitory activity. Replacement of the synthetically complex noviose sugar with simple aromatic side chains produced analogs that maintain moderate cytotoxic activity against MCF7 and SkBR3 breast cancer cell-lines. Rationale for the preparation of des-noviose novobiocin analogs in addition to their synthesis and biological evaluation are presented herein. | en_US |
dc.publisher | Elsevier | en_US |
dc.rights | This article is made available under an Attribution-NonCommercial-NoDerivs 3.0 United States (CC BY-NC-ND 3.0 US) License. | en_US |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/3.0/us/ | en_US |
dc.title | Synthesis and biological evaluation of arylated novobiocin analogs as Hsp90 inhibitors | en_US |
dc.type | Article | en_US |
kusw.kuauthor | Kusuma, Bhaskar Reddy | |
kusw.kuauthor | Duerfeldt, Adam S. | |
kusw.kuauthor | Blagg, Brian S. J. | |
kusw.kudepartment | Medicinal Chemistry | en_US |
dc.identifier.doi | 10.1016/j.bmcl.2011.09.073 | en_US |
dc.identifier.orcid | https://orcid.org/0000-0002-3130-9890 | |
kusw.oaversion | Scholarly/refereed, author accepted manuscript | en_US |
kusw.oapolicy | This item meets KU Open Access policy criteria. | en_US |
dc.identifier.pmid | PMC3242434 | en_US |
dc.rights.accessrights | openAccess | |